Exciting News for Physicians: GRAIL’s Galleri Test Now Available in the US
In a recent press release, GRAIL, a leading healthcare and biotech company, announced that its groundbreaking multi-cancer early detection test, Galleri, is now directly accessible to physicians in the United States through a collaboration with Quest Diagnostics. This collaboration aims to streamline the provider and patient experience, bringing a new level of convenience and accessibility to cancer screening.
What is Galleri?
Galleri is a blood test designed to detect over 50 types of cancers, including breast, prostate, and lung cancer, with a single sample. The test analyzes cell-free DNA circulating in the blood, looking for signals of cancer. With an overall sensitivity of 50.2% and a specificity of 99.5%, Galleri is a significant step forward in early cancer detection.
Collaboration with Quest Diagnostics
Quest Diagnostics, a leading diagnostic information services company, will offer Galleri as a lab test orderable through its Physcians Order Entry system. This collaboration allows physicians to order the test directly for their patients, streamlining the process and making it more accessible. The test results will be reported back to the ordering physician, enabling them to discuss the findings with their patients and make informed decisions regarding further diagnostic steps.
Impact on Patients
The collaboration between GRAIL and Quest Diagnostics means that patients in the US can now benefit from Galleri’s advanced cancer detection capabilities without the need for a referral or extensive coordination with specialized centers. This could lead to earlier cancer detection, improved patient outcomes, and increased peace of mind for those at risk. Additionally, the convenience of ordering the test through their regular healthcare provider may encourage more people to undergo cancer screening, ultimately leading to better population health.
Impact on the World
The availability of Galleri through Quest Diagnostics marks a significant milestone in the global fight against cancer. This collaboration has the potential to revolutionize cancer screening by making it more accessible, convenient, and efficient. As more countries and healthcare systems adopt similar approaches, we could see a global shift towards early detection and improved cancer outcomes. This could lead to a reduction in cancer-related deaths, a better quality of life for cancer patients, and overall cost savings for healthcare systems.
Conclusion
The collaboration between GRAIL and Quest Diagnostics is an exciting development in the world of cancer screening. With the availability of Galleri directly to US physicians, we can expect earlier cancer detection, improved patient outcomes, and increased convenience for those at risk. Furthermore, this collaboration has the potential to set a global precedent, paving the way for more accessible, efficient, and effective cancer screening programs. Stay tuned for more updates on this groundbreaking technology and its impact on the world of healthcare.
- GRAIL’s Galleri test now available to US physicians through Quest Diagnostics
- Blood test detects over 50 types of cancers with high sensitivity and specificity
- Collaboration aims to streamline provider and patient experience
- Patients can benefit from earlier cancer detection and improved outcomes
- Global potential to revolutionize cancer screening and reduce deaths
